Adaptimmune is merging with TCR² Therapeutics in a bid to create a T cell therapy developer aimed at solid tumors. The all-stock deal brings together both companies’ lead candidates — Adaptimmune’s afami-cel, which targets MAGE-A4, and TCR²’s mesothelin-targe…